The efficacy and safety of donepezil in patients with alzheimer’s disease: Results of a us multicentre, randomized, double-blind, placebo-controlled Trial

Dementia and Geriatric Cognitive Disorders

Volumn 7, Issue 6, 1996, Pages 293-303

  Rogers, Sharon L ^a   Friedhoff, Lawrence T ^a  

^a EISAI INC   (United States)

Author keywords

Alzheimer s disease; Donepezil; Selective acetylcholinesterase inhibitor

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; COMMON COLD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; VERTIGO; VOMITING;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; ERYTHROCYTES; FEMALE; HUMANS; INDANS; MALE; MENTAL HEALTH; MIDDLE AGED; OSMOLAR CONCENTRATION; PIPERIDINES; PLACEBOS;

EID: 10244259208     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106895     Document Type: Article

References (31)

1. Selkoc DJ: Aging brain, aging mind. Sci Am 1992;267:97-103.
2. Katzman R, Saitoh T: Advances in Alzheimer's disease. FASEBJ 1991;5:278-286.
3. Becker RE: Therapy of the cognitive deficit in Alzheimer's disease: The cholinergic system: in Becker R. Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston. Birkhäuser, 1991, pp 1-30.
4. Mesulam M-M: Butyrylcholincsterases in Alzheimer's disease: in Giacobini E. Becker R (eds): Alzheimer's Disease: Therapeutic Strategics. Boston. Birkhäuscr, 1994, pp 79-83.
5. Taylor P: Anticholinesterase agents; in Gilman AG. Rati TW. Nics AS. Taylor P (eds): Goodman and Gilman's the Pharmacological Basis of Therapeutics, ed 8. New York, McGraw-Hill, 1993, pp 131-149.
6. Summers WK, Majovski LV, Marsh GM, Ta-chiki K, Kling A: Oral tetrahydroaminoacri-dinc in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-1245.
7. Davis KL, Thai U, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Crachman DA, Schneider LS, Whitchouse PJ, Hoover TM: A double-blind, placebo-controlled multicenter study of tacrine forAlzheimer'sdisease. N Engl J Med 1992;327:1253-1259.
8. Stern Y, Sano M, Maycux R: Long-term administration of oral physostigminc in Alzhci-mer'sdisease. Neurology 1988;38:1837-1841.
9. Cardozo MG, Iimura Y, Sugimoto H, Yamani-shi Y. Hopfinger AJ: QSAR analysis of the substituted indanone and bcnzylpipcridinc rings of a scries of indanonc-bcnzylpipcridinc inhibitors of actylcholinestcrase. J Med Chem 1992; 35:584-589.
10. Cardozo MG, Kawai T, limura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ: Conformational analysis and molecular shape comparisons of a series of indanonc-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem I992;35: 590-601.
11. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K: Synthesis and anti-cholincstcrasc activity of I -bcnzyI-4-[(5,6-dimcthyoxy- l-indanon-2-yl) methyl] piperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lett 1992;2:871-876.
12. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K: Inhibitory' action of done-pczil, a novel acetylcholinesterase inhibitor, on Cholinesterase. Comparison with other inhibitors; in Nagatsu T. Fisher A, Yoshida M (eds): Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson's Diseases. New York. Plenum Press, 1990. vol 2, pp 409-413.
13. Rogers SL, Yaminishi Y, Yamatsu K: E2020 -the pharmacology of a piperidine Cholinesterase inhibitor, in Becker R, Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston. Birkhäuser, 1991, pp 314-320.
14. Sherman KA: Pharmacodynamics of oral E2020 and tacrine in humans: Novel approaches; in Becker R, Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston, Birkhäuscr, 1991, pp 321 -328.
15. Ogurc H, Kosasa T, Araki S, Yamanishi Y, Yamatsu K: Behavioral study of E2020, a novel, centrally acting acetylcholinesterase inhibitor. Soc Ncurosci 1980:14:60.
16. Ogurc H, Kosasa T, Araki S, Yamanishi Y, Yamatsu K Diagnostic and statistical manual of mental disorders, ed 3, revised. Washington, DC. American Psychiatric Association, 1987.
17. McKhann G, Drachnnin D, Folstein M, Katz-man R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Sendees Task Force on Alzheimer’s Disease. Neurology 1984:34:939-944.
18. Folstein MF, Folstein SE, McHugh PR:’Mini-Mental State', A practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res 1975:12:189-198.
19. Hughes CD, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia, Br J Psychiatry 1982:140:556-572.
20. World Medical Association: Declaration of Helsinki. Recommendations guiding medical doctors in biomedical research involving human subjects. Med J Aust 1976:1:206-207.
21. Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville, National Institute of Mental Health, 1976. Publication number 76-388.
22. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figicl G: Mild senile dementia of the Alzheimer type. Evaluation of intervention. Ann Neurol 1992:31:242-249.
23. Blau TH: Quality of life, social indicators and criteria of change. Prof Psychol 1977:8:464-473.
24. Haginaka J, Seyama C: Determination of cn-antionters of l-benzyl-4-(5,6-dimethoxy-l-in-danon)-2-yl]mclhvl piperidine hydrochloride (E2020), a centrally acting acetyl Cholinesterase inhibitor. in plasma by liquid chromatography with fluorimetric detection, i Chromatogr 1992:577:95-102.
25. Matsui K, Oda Y, Ohe H, Tanaka S, Asakawa N: Direct determination of E2020 cnantiomers in plasma by liquid chromatography - mass spectography and column-switching techniques. J Chromatogr 1995;694A:209-21
26. Hulsc JD, Rogers SL, Friedhoff LT, Sukovaty R, Pedersen JE, Lee JW: A radioenzyme assay of acetylcholinesterase activity in red blood cells and its correlation with l-benzyl-4-[(5,6-dimcthoxy-l-indanon)-2-yl] methyl piperidine HCI. Phalm Res I992;9:S228.
27. National Adverse Drug Reaction Directory. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms, ed 3. Rockville. Department of Health and Human Services. Food and Drug Administration. 1989.
28. Becker R, Giacobini E: Mechanism of Cholinesterase inhibition in senile dementia of the Alzheimer's disease type: Clinical, pharmacological and therapeutic aspects. Drug Dev Res 1988:12:163-195.
29. Becker R, Giacobini E: Pharmacokinetics and pharmacodynamics of acetyl Cholinesterase and inhibitors: Can acetyl choline levels in the brain be improved in Alzheimer's disease? Drag Dev Res 198S: 14:235-246.
30. Thal U, Maasur DM, Fuld PA, Sharplcss NS, Davies P: Memory improvement with oral phvsostigmine and lecithin in Alzheimer's disease: in Kaizman R (ed): Banbury Report: Biological Aspects of Alzheimer's Disease, cd 9. Cold Spring I larbor. Cold Spring I larbor Laboratory. 1983. vol 15. pp 461-470.
31. Becker R, Colliver J, Elble R, Feldman E, Gia-eobim E, Kumar V, Mnrkwcll S, Moricarty P, Parks R, Shillcult S, Unni L, Vicari S, Womack C, Zee R: Effects of metrifonate, a long acting Cholinesterase inhibitor, in Alzheimer's disease: Report of an open trial. Drug Dew Res 1990:19:425-434.